Jazz Pharmaceuticals PLC 8-K filings

Jazz Pharmaceuticals announces a definitive agreement to acquire Actio Biosciences for an upfront payment of $820 million, plus potential milestone payments up to $500 million.

Jazz Pharmaceuticals announced its definitive agreement to acquire Actio Biosciences for $820 million upfront, plus up to $500 million in contingent consideration, to expand its rare epilepsy portfolio with the addition of ABS-1230.

Jazz Pharmaceuticals announced strong second quarter 2026 financial results, exceeding expectations with record total revenues of $1.2 billion and raising its full-year revenue guidance.

Jazz Pharmaceuticals plc shareholders approved director elections, auditor ratification, executive compensation, and share issuance authorities at the 2026 Annual General Meeting.

Jazz Pharmaceuticals announced first quarter 2026 financial results, with total revenues reaching $1.1 billion, a 19% year-over-year increase, driven by strong commercial execution across its franchises.

Jazz Pharmaceuticals announced record 2025 total revenues of $4.3 billion, driven by key product growth and provided optimistic 2026 financial guidance.

Jazz Pharmaceuticals expects to meet its 2025 total revenue guidance and highlights strong performance across its rare disease portfolio, including key product sales and pipeline advancements.

Jazz Pharmaceuticals announced positive top-line results from its Phase 3 HERIZON-GEA-01 trial for Ziihera in HER2-positive gastroesophageal adenocarcinoma.

Jazz Pharmaceuticals reported strong third-quarter 2025 financial results, driven by robust growth in key products and significant FDA approvals, while raising its full-year non-GAAP earnings guidance.

Jazz Pharmaceuticals plc announced the appointment of Dr. Ted Love to its Board of Directors and the retirement of Kenneth W. O'Keefe, effective December 1, 2025.

Jazz Pharmaceuticals has reached a global settlement with Avadel Pharmaceuticals, resolving all patent infringement and anticompetitive claims, involving a $90 million payment and mutual royalty agreements.

Jazz Pharmaceuticals reported a significant net loss in Q2 2025 primarily due to a large acquired in-process R&D expense from the Chimerix acquisition, while updating its full-year 2025 financial guidance.

Jazz Pharmaceuticals plc shareholders overwhelmingly approved all four proposals, including director elections, auditor ratification, executive compensation, and share allotment authority, at the 2025 Annual General Meeting.

Jazz Pharmaceuticals plc announced the appointment of Renee Gala as President and Chief Executive Officer, effective August 11, 2025, succeeding co-founder Bruce Cozadd who will remain Chairperson of the Board.

Jazz Pharmaceuticals reports $898 million in total revenues for 1Q25, driven by growth in Xywav and Epidiolex, and updates its 2025 financial guidance to reflect the Chimerix acquisition and Xyrem antitrust litigation settlements.

Jazz Pharmaceuticals completes the acquisition of Chimerix for approximately $935 million in cash, adding dordaviprone to its oncology portfolio.

Jazz Pharmaceuticals has agreed to a $145 million settlement with indirect Xyrem purchasers to resolve antitrust claims related to patent litigation settlement agreements with generic drug manufacturers.

Jazz Pharmaceuticals is set to acquire Chimerix, Inc. for $8.55 per share, aiming to expand its portfolio through a strategic merger.

Jazz Pharmaceuticals is set to acquire Chimerix for $8.55 per share in cash, a deal valued at approximately $935 million, to expand its oncology pipeline with dordaviprone, a treatment for rare brain tumors.

Jazz Pharmaceuticals announces strong 2024 financial results with record revenues and provides promising financial guidance for 2025, driven by growth in its diversified portfolio.

Jazz Pharmaceuticals expects to meet its previously announced revenue guidance for 2024 and provided updates on its key pipeline programs at the J.P. Morgan Healthcare Conference.

Jazz Pharmaceuticals CEO Bruce Cozadd will retire by the end of 2025 after a successor is found, but will remain as Chairperson of the Board.

Jazz Pharmaceuticals has amended its credit agreement, increasing its revolving credit facility to $885 million and extending the maturity date to November 2029.

The FDA has granted accelerated approval to Jazz Pharmaceuticals' Ziihera for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer.

Jazz Pharmaceuticals announced a 14% year-over-year revenue increase from key growth drivers in the third quarter of 2024 and reaffirmed its full-year revenue guidance.

Jazz Pharmaceuticals will terminate its existing Palo Alto lease in 2025 and move to a new location, maintaining its U.S. operations in California and Pennsylvania.

Jazz Pharmaceuticals' subsidiary, Jazz Investments I Limited, successfully closed a $1 billion private offering of exchangeable senior notes due 2030, including the full exercise of the initial purchasers' option, and repurchased $150 million of its ordinary shares.

Jazz Pharmaceuticals secured a partial injunction against Avadel Pharmaceuticals, restricting the marketing and expansion of Avadel's Lumryz for certain indications, following a patent infringement lawsuit.

Jazz Pharmaceuticals announced a 15% year-over-year revenue increase driven by key growth products and updated its 2024 financial guidance.

Jazz Pharmaceuticals held its 2024 annual general meeting, where shareholders voted on director elections, auditor ratification, executive compensation, and share issuance authority.